MONUMENT-RE-LIMITED
Monument Re announced today that, subject to necessary Irish High Court and regulatory approvals, it has agreed to acquire the closed-block portfolio of variable annuities from Athora Ireland plc, a wholly-owned subsidiary of Athora Holding Ltd. Financial terms of the transaction were not disclosed.
“We are pleased to have reached agreement with Athora to acquire this block of business which further reinforces our position as the market leading consolidator in Ireland ,” said Manfred Maske, CEO of Monument Re.
About Athora Holding Ltd.
Athora is a specialised insurance and reinsurance group fully focused on the European market. Athora dedicates its focus, capital, time and technical insights to offering its customers a stable, long-term performance on its products. Athora's principal subsidiaries are Athora Netherlands N.V. (Amstelveen, Netherlands), Athora Belgium N.V./S.A. (Brussels), Athora Lebensversicherung AG (Wiesbaden, Germany), Athora Ireland plc (Dublin) and Athora Life Re Ltd. (Bermuda). The Athora group employs some 2,400 staff and has approximately 3 million policyholders for total consolidated assets of approximately €80 billion (as at 30 June 2020). For further information, go to: www.athora.com .
About Athora Ireland
Athora Ireland plc is an Irish insurance company focused on providing reinsurance solutions to insurers and the efficient management of a portfolio of variable annuities for some 13,000 policyholders, predominantly in the UK, representing about €1 billion of funds under management. For further information, go to: www.athora.com/ie .
About Monument Re and Monument Life Insurance
Monument Re Limited is a life Reinsurance and Insurance Holding Company with a presence in Bermuda, Ireland, Belgium, Luxembourg, The Netherlands, the Isle of Man and Guernsey, with branches in Spain, Italy, France and Germany. Monument Re operates as a reinsurer and acquirer of European asset-intensive portfolios. Through this strategy, Monument Re assumes asset-based risks within its risk appetite and efficiently operates these businesses or portfolios.
Monument Re is subject to Group Supervision by the Bermuda Monetary Authority.
Monument Life Insurance DAC is an Irish insurance company regulated by the Central Bank of Ireland and 100% owned by Monument Re Limited.
To learn more, please visit www.monumentregroup.com or contact Fiona Davies at info@monumentregroup.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210303005109/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Mastering Complexity & Increasing Efficiency: CES 2026: dSPACE Demonstrates Test and AI Solutions for SDV Development16.12.2025 14:02:00 CET | Press release
At CES 2026, dSPACE will showcase end-to-end test solutions that enable vehicle manufacturers to efficiently master the increasing complexity in the development of software-defined vehicles. At booth 4500 in West Hall, dSPACE will present a comprehensive validation portfolio with AI-supported software-in-the-loop and hardware-in-the-loop solutions for accelerated vehicle development. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251216117958/en/ At CES 2026, dSPACE will present a comprehensive validation portfolio with AI-supported software-in-the-loop and hardware-in-the-loop solutions for accelerated SDV development. AI is a strategic enabler throughout the entire development and test process. dSPACE has been exploring how the latest developments in generative and agentic AI technologies can support software-in-the-loop (SIL) testing and enable CI/CD pipelines for automated validation. In an exhibit, dSPACE will demonstra
PPG achieves REDCert² sustainable raw material certification at two key European sites16.12.2025 14:01:00 CET | Press release
PPG (NYSE: PPG) today announced that its Architectural Coatings manufacturing sites in Amsterdam, the Netherlands and Søborg, Denmark have received REDCert² certification, which verifies the use of sustainable raw materials through a certified chain of custody. REDCert² uses the mass balance approach, a recognized method for attributing the sustainability value of certified inputs. This ensures that PPG’s products reflect responsible sourcing throughout the manufacturing process and reinforces the company’s commitment to delivering high-performing, sustainably advantaged solutions to customers across Europe. “This certification supports our broader goal of integrating sustainability and productivity into our operations and our commitment to transparent manufacturing,” said Mats Hagerstrom, PPG head of sustainability, EMEA, Architectural Coatings. “It helps us deliver products that meet high performance standards while supporting our customers’ environmental objectives.” The certified s
FIFA World Cup™ Trophy Tour by Coca-Cola to Begin Global Journey Ahead of FIFA World Cup 2026™16.12.2025 14:00:00 CET | Press release
Coca-Cola and FIFA celebrate 20 years of FIFA World Cup™ Trophy Tour by Coca-Cola The Coca-Cola Company and FIFA are kicking off the sixth FIFA World Cup™ Trophy Tour by Coca-Cola, giving thousands of fans across the globe the opportunity to see the original FIFA World Cup™ Trophy ahead of FIFA World Cup 2026™. FIFA World Cup 2026 is set to be the biggest yet—spanning three host nations, Canada, Mexico and the United States, with more teams, more matches and more celebrations than ever before. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251216393608/en/ FIFA World Cup™ Trophy Tour by Coca-Cola As a long-standing partner of FIFA, Coca-Cola has the exclusive rights to the FIFA World Cup Trophy Tour by Coca-Cola. Beginning Jan. 3, 2026, in Riyadh, Saudi Arabia, the original FIFA World Cup Trophy will visit 30 FIFA Member Associations across 75 stops and more than 150 tour days, giving fans around the world a once-in-a-lifeti
1GLOBAL Empowers Revolut to Offer Mobile Plans in Poland16.12.2025 13:04:00 CET | Press release
1GLOBAL, a technology-driven global mobile communications provider, strengthens its partnership with Revolut, expanding the leading neobank’s mobile data plan offering to the Polish market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251216769985/en/ 1GLOBAL strengthens its partnership with Revolut, expanding the leading neobank’s mobile data plan offering to the Polish market. By integrating 1GLOBAL’s eSIM capability into its multi-service app, Revolut’s customers in Poland who signed up to the waitlist can now enjoy bundled mobile plans that include competitively priced domestic data plans starting at zł 25 per month (approx. €6.00 per month) with unlimited calls and texts in Poland and the EU, in just a few taps. For 1GLOBAL, this expansion marks another milestone in the company’s embedded telco services strategy. The services are trusted by more than 4,000 corporate partners across a variety of industries including fi
Dompé Doses First Patients in Europe and US in Phase 3 Studyof Isocyclosporin for Atopic Keratoconjunctivitis16.12.2025 13:00:00 CET | Press release
Atopic keratoconjunctivitis(AKC) is a chronic inflammatory disease of the eye that is frequently associated with atopic conditions, and limited disease awareness often leads to delayed or missed diagnosis. Isocyclosporin is a novel, dual inhibitor oftwo critical immunepathways in ocular inflammation like AKC. Dompé, a leading biopharmaceutical company with operations in Italy and the U.S., announced the first patients have been enrolled in a Phase 3 study of Isocyclosporin for the treatment of atopic keratoconjunctivitis (AKC). Isocyclosporin is a dual inhibitor of transient receptor potential (TRP) cation channel, mucolipin subfamily, member 2 (TRPML2) and calcineurin, key regulators of immune and inflammatory response in chronic inflammatory eye diseases. The Phase 3 trial is a multicenter, randomized, double-masked study comparing isocyclosporin against vehicle control in improving ocular signs and symptoms after six weeks of treatment. “This milestone underscores Dompé’s commitment
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom